跳至主要内容
临床试验/NCT02146807
NCT02146807已完成不适用

LASER TREATMENT OF TATTOOS WITH A DUAL WAVELENGTH PICOSECOND LASER

Syneron Medical5 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2013年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
5
主要终点
Global percentage of tattoo clearance

研究概览

简要总结

The purpose of this study is to determine whether Pico laser is effective and safe in the treatment of unwanted tattoos.

详细描述

The Investigational device is a dual wavelength laser system developed for treatment of pigmented lesions and for tattoo removal. The base unit is a GentleMax Pro laser system modified to emit light at wavelengths of 532 and 1064 nm and deliver pulse energy up to 400mJ, and pulse duration of 700 ps.

A multicenter study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has Fitzpatrick skin type I-IV
  • Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove them
  • Is willing to consent to participate in the study
  • Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits

排除标准

  • Is hypersensitive to light exposure
  • Has an active sun tan
  • Has Fitzpatrick skin type V or VI
  • Has active localized or systemic infection
  • Is taking medication(s) for which sunlight is a contraindication
  • Has a history of squamous cell carcinoma or melanoma
  • Has a history of keloid scarring
  • Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
  • Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
  • Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period
  • Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine

结局指标

主要结局

Global percentage of tattoo clearance

时间窗: 3 months post the final treatment

Global percentage of tattoo clearance evaluated by blinded observers using post treatment photographs compared to baseline photographs.

次要结局

  • Rate of tattoo clearance(3 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验